AWAKN Life Sciences Inc.

Recent News

  • Celia Morgan, Professor of Psychopharmacology at University of Exeter and Leading Ketamine Investigator, Joins AWAKN Life Sciences

    Toronto, Ontario--(Newsfile Corp. - October 2, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Professor Celia Morgan to its Scientific Advisory Board (SAB).Celia Morgan is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom. She is one Europe's leading Ketamine researchers & investigators and the academic lead for the Exeter Translational Addiction Partnership. Prof. Morgan's research focuses on examining both the benefits and side effects of recreational drugs on...

    2020-10-02 9:00 AM ET
  • Dr. Michael Mithoefer & Ann Mithoefer from MAPS Join AWAKN's Scientific Board

    Toronto, Ontario--(Newsfile Corp. - September 24, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Dr. Michael Mithoefer and Ann Mithoefer to its Scientific Advisory Board (SAB). Dr. Mithoefer, Senior Medical Director for Medical Affairs, Training and Supervision at MAPS Public Benefit Corporation (MPBC), has, has worked with MAPS since 2000, while Ann Mithoefer, a registered Nurse and Lead MDMA-Assisted Psychotherapy PTSD Investigator at MAPS, has worked with MAPS since 2004. Together Dr. Michael...

    2020-09-24 12:06 PM ET
  • AWAKN Life Sciences Launches Clinical Research Division with Prof. David Nutt & Dr. Ben Sessa Identifying Suitable Studies Across Europe & North America

    Toronto, Ontario--(Newsfile Corp. - September 8, 2020) - AWAKN Life Sciences Inc ("AWAKN"), the European psychedelic assisted psychotherapy company, today announces the launch of its Commercial Clinical Research Division.AWAKN's purpose is broadening access to psychedelic assisted psychotherapy and integrating these services into mainstream mental healthcare in Europe across three business divisions of Clinical Research, Therapeutic Clinics, and Practitioner Training. AWAKN's Commercial Clinical Research Division focuses on sponsoring, designing and delivering existing compound, new indication psychedelic assisted psychotherapy clinical trials,...

    2020-09-08 8:00 AM ET
  • Dr. Matthew Johnson Joins AWAKN Life Sciences

    Toronto, Ontario--(Newsfile Corp. - September 2, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Dr. Mathew Johnson, Ph.D, to its Scientific Advisory Board (SAB).Dr. Johnson is one of the world's most published scientists on the human effects of psychedelics. He has conducted seminal research in the behavioral economics of drug use, addiction, and risk behavior through his role of Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University.Dr. Johnson published psychedelic safety...

    2020-09-02 3:08 PM ET
  • AWAKN Life Sciences Partners with Drug Science in the UK

    Toronto, Ontario--(Newsfile Corp. - July 16, 2020) - AWAKN Life Sciences Inc ("AWAKN"), the psychedelic healthcare company focused on the UK and European markets, announced the new partnership to coincide with Drug Science's inaugural Psychedelics Working Group meeting that took place this week on 14th July 2020.Founded in 2010 by Professor David Nutt, Drug Science works to provide evidence for widespread application of psychedelic drugs within public health models. Its aim is to break the barriers of 50 years of...

    2020-07-16 8:00 AM ET
  • Professor David Nutt Joins AWAKN Life Sciences

    Toronto, Ontario--(Newsfile Corp. - July 7, 2020) - AWAKN Life Sciences Inc. ("AWAKN") is pleased to announce the appointment of Professor David Nutt as Chairman of its newly formed Scientific Advisory Board (SAB). Professor David Nutt is a world renowned neuroscientist, leading global authority on drug policy reform and former chief drug advisor to the UK government. He serves as the Edmond J. Safra Professor of Neuropsychopharmacology and director of the neuropsychopharmacology unit in the Division of Brain Sciences...

    2020-07-07 7:57 AM ET
  • Psychedelic Medical Start-Up AWAKN Life Sciences Enters the UK Market with Dr. Ben Sessa

    Toronto, Ontario--(Newsfile Corp. - June 18, 2020) - AWAKN Life Sciences Inc. ("AWAKN"), has signed a binding investment agreement to acquire a controlling interest in Mandala Therapy Limited, the UK based psychedelic clinical practice run by acclaimed author, researcher and consultant psychiatrist, Dr. Ben Sessa. Dr. Sessa will become AWAKN's Chief Medical Officer and will open the UK's first psychedelic-assisted psychotherapy clinic over the coming months. Under his leadership, AWAKN intends to oversee a revolutionary shift in the treatment...

    2020-06-18 9:00 AM ET